The FDA has given Novartis the green light to market Farydak (panobinostat), a potent pan-deacetylase inhibitor, as a treatment for multiple myeloma, a disease that affects about 21,700 Americans each year, killing 10,710.
But the approval wasn't smooth.


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

